No Data
Chengda Pharmaceutical (301201.SZ): Expected loss of 21 million to 29 million yuan for the fiscal year 2024.
Glonghui, January 16 – Chengda Pharmaceutical (301201.SZ) announced its performance forecast for 2024, projecting a net income loss attributable to the shareholders of the listed company of 21 million to 29 million yuan, compared to a profit of 90.98 million yuan in the same period last year; the net income loss after deducting non-recurring gains and losses is estimated to be 50 million to 60 million yuan, compared to a profit of 53.82 million yuan in the same period last year. The revenue for the reporting period is expected to decrease by approximately 16% to 27% year-on-year. Among them: the sales revenue of the Active Pharmaceutical Ingredient business is expected to decline by about 33% year-on-year, mainly due to overstocking of pharmaceutical-grade L-carnitine by customers in 2023, according to the report.
Chengda Pharmaceutical: 2024 Annual Performance Forecast
Chengd Pharmaceutical (301201.SZ): Some fundraising projects have been completed.
On January 3, Gelonghui reported that Chengda Pharmaceutical Co., Ltd. (301201.SZ) announced that recently, the fundraising investment projects "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project" have been completed and reached the designated usable status, meeting the project completion conditions. Therefore, the company has decided to conclude the "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project."
Chengda Pharmaceutical (301201.SZ) has been re-certified as a high-tech enterprise.
On January 3, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) recently received the "High-tech Enterprise Certificate" jointly issued by the Zhejiang Provincial Department of Economy and Information Technology, the Zhejiang Provincial Department of Finance, and the State Administration of Taxation Zhejiang Provincial Tax Service. The certificate number is GR202433007629, the issuance date is December 6, 2024, and the validity period is three years.
Chengda Pharmaceutical (301201.SZ): Active Pharmaceutical Ingredients such as Edaravone Sodium and Rivaroxaban are currently under registration application.
On December 17, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated in a recent investor relations activity that the Active Pharmaceutical Ingredient L-carnitine has been approved by the regulatory authorities of several countries and obtained the CEP certification in Europe, covering quality system certification for major global markets. The Active Pharmaceutical Ingredient Brinfido has been approved by South Korea's MFDS, while the Active Pharmaceutical Ingredients Aflibercept and Rivaroxaban are in the process of registration. The Active Pharmaceutical Ingredient Daglizhuo passed CDE approval in November 2024, further enriching the company's product line.
Chengda Pharmaceutical (301201.SZ): The buyback has been completed, with a total of 2.10% of the company's shares repurchased.
On December 11, Gelianghui reported that Chengda Pharmaceutical (301201.SZ) announced that as of the date of this announcement, the company has repurchased a total of 3,244,700 shares through a special securities account for share repurchase via centralized bidding, accounting for 2.10% of the company's current total share capital (based on the current total share capital of 154,713,824 shares). The highest Fill Price was 22.21 yuan/share, the lowest Fill Price was 14.63 yuan/share, and the total amount of the repurchase was 57,061,614.15 yuan (excluding transaction fees), with the repurchase amount not lower than the lower limit of the total amount of the repurchase funds in the repurchase plan.
